KIT and RAS signalling pathways in testicular germ cell tumours: new data and a review of the literature
Open Access
- 15 June 2007
- journal article
- review article
- Published by Wiley in International Journal of Andrology
- Vol. 30 (4) , 337-349
- https://doi.org/10.1111/j.1365-2605.2007.00769.x
Abstract
Testicular germ cell tumours (TGCTs) are the leading cause of cancer deaths in young male Caucasians. Identifying changes in DNA copy number can pinpoint genes involved in tumour development. We defined the smallest overlapping regions of imbalance in TGCTs using array comparative genomic hybridization analysis. Novel regions, or regions which refined those previously reported, were identified. The expression profile of genes from 12p, which is invariably gained in TGCTs, and amplicons defined at 12p11.2‐12.1 and 4q12, suggest KRAS and KIT involvement in TGCT and seminoma development, respectively. Amplification of these genes was not found in intratubular germ cell neoplasia adjacent to invasive disease showing these changes, suggesting their involvement in tumour progression. Activating mutations of RAS genes (KRAS or NRAS) and overexpression of KRAS were mutually exclusive events. These, correlations between the expression levels of KIT, KRAS and GRB7 (which encodes an adapter molecule known to interact with the KIT tyrosine kinase receptor) and other reported evidence reviewed here, are consistent with a role for activation of KIT and RAS signalling in TGCT development. In order to assess a role for KIT in seminomas, we modulated the level of KIT expression in TCam‐2, a seminoma cell line. The likely seminomatous origin of this cell line was supported by demonstrating KIT and OCT3/4 overexpression and gain of 12p material. Reducing the expression of KIT in TCam‐2 through RNA inhibition resulted in decreased cell viability. Further understanding of KIT and RAS signalling in TGCTs may lead to novel therapeutic approaches for these tumours.Keywords
This publication has 70 references indexed in Scilit:
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced CancerJournal of Clinical Oncology, 2005
- Mutations of BRAF and RAS are rare events in germ cell tumoursInternational Journal of Cancer, 2004
- Germinal tumor invasion and the role of the testicular stromaThe International Journal of Developmental Biology, 2004
- High‐resolution comparative genomic hybridization detects extra chromosome arm 12p material in most cases of carcinoma in situ adjacent to overt germ cell tumors, but not before the invasive tumor developmentGenes, Chromosomes and Cancer, 2003
- Expression profile of genes from 12p in testicular germ cell tumors of adolescents and adults associated with i(12p) and amplification at 12p11.2–p12.1Oncogene, 2003
- The immunohistochemical expression pattern of Chk2, p53, p19INK4d, MAGE‐A4 and other selected antigens provides new evidence for the premeiotic origin of spermatocytic seminomaHistopathology, 2003
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003
- Spermatocytic seminoma as compared to classical seminoma: An immunohistochemical and DNA flow cytometric studyAPMIS, 1999
- No recurrent structural abnormalities apart from i(12p) in primary germ cell tumors of the adult testisGenes, Chromosomes and Cancer, 1995